Anna Ceribelli

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2015 · 478 citations · Full text

Factorial phase III randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study

Cesare Gridelli, Ciro Gallo, Anna Ceribelli et al. · The Lancet Oncology · 2007 · 101 citations

Medicine, Metronomic Therapy, Pharmacology +6

Clinical Implications of KRAS Mutations in Lung Cancer Patients Treated with Tyrosine Kinase Inhibitors: An Important Role for Mutations in Minor Clones

Antonio Marchetti, Michèle Milella, Lara Felicioni et al. · Neoplasia · 2009 · 99 citations · Full text

A novel clinical prognostic score incorporating the number of resected lymph-nodes to predict recurrence and survival in non-small-cell lung cancer

Emilio Bria, Michèle Milella, Isabella Sperduti et al. · Lung Cancer · 2009 · 84 citations

Prognostic Evaluation, Prognostic Biomarkers, Surgical Oncology +12

Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels

Camillo F. Pollera, Anna Ceribelli, M Crecco et al. · Investigational New Drugs · 1997 · 62 citations

Cardiovascular Disease, Infusion Gemcitabine, Medicine +8